No Data
No Data
Clear Street Initiates Akero Therapeutics(AKRO.US) With Buy Rating, Announces Target Price $49
Express News | Akero Therapeutics Announces Upcoming Poster and Oral Presentations at the Easl Congress 2025
Akero Therapeutics Announces Upcoming Poster and Oral Presentations at the EASL Congress 2025
Akero Therapeutics Initiated With a Buy at Clear Street
$AKRO Stock Is up 2% Today. Here's What We See in Our Data.
Insiders At Akero Therapeutics Sold US$1.6m In Stock, Alluding To Potential Weakness